Methylomics is a company that applies state of the art molecular diagnostic technologies for interrogation of the epigenome by genome wide DNA methylation profiles in healthy and diseased tissue to develop novel assays for cancer progression and therapy response. Focus of our research and product development at this moment are cancers of the colorectal region, skins and cancers of the uro-genital zone, including cervical, ovarian and endometrial cancers. Methylomics is a young company founded in 2018, located in Rijswijk the Netherlands.